A Phase 1, Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Patients with Injectable Solid Tumors
Principal investigator: Katriina Peltola
Trial site: HUS Comprehensive Cancer Center
Link to the ClinicalTrials.gov study website
